Biotricity Inc. (OTCQB: BTCY) announced on January 15, 2025, a partnership with B-Secur, a biosensing technology leader, to create an advanced, device-neutral platform for integrated heart monitoring.
This collaboration combines B-Secur's FDA-cleared HeartKey® technology, which includes algorithms and analytics, with Biotricity's existing medical and consumer diagnostic solutions. The platform aims to enhance capabilities for Ambulatory Cardiac Monitoring.
The partnership is designed to empower Integrated Delivery Networks, healthcare providers, health systems, and Independent Diagnostic Testing Facilities. It addresses critical gaps in cardiac care delivery by improving accessibility and efficiency for both providers and patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.